Podcasts about Bayer

https://www.youtube.com/watch?v=F6vA9ensrzw Podcast audio: In this episode of The Ayn Rand Institute Podcast, Ben Bayer and Nikos Sotirakopoulos critique a recent Wall Street Journal article that tries to explain Zohran Mamdani's rise and the persistence of socialism in American politics. Among the topics covered: Why socialism is not an innate impulse or the product of ignorance of history; Why idealism alone does not explain socialism's popularity; How miseducation about capitalism contributes to the endurance of socialism; Why you can't fight woke ideology while upholding Christianity's altruistic ethic; How to defeat socialism. Recommended in this podcast are Ayn Rand's Atlas Shrugged, her article “Faith and Force: The Destroyers of the Modern World,” the Ayn Rand Lexicon entry on Socialism, and Bayer's articles “The Dishonesty of ‘Real Socialism Has Never Been Tried'” and “The Old Morality of the New Religions.” The podcast was recorded on August 25, 2025 and posted on August 28, 2025. Listen and subscribe wherever you get your podcasts. Watch archived podcasts here.

TT The Companies That Own it All: Part 1 In this show, the teenagers (Deven and Ethan) talk about how most of the large companies such as Hershey's, Kellogg's, Coca-Cola, and many more, are owned by one company. In this show, you will learn how most of the things that you eat, drink, and use in your everyday life are owned by Bayer. As well as how BlackRock, Vanguard, and State Street own large shares in Bayer, as well as most of the other large companies that are well known and very powerful. How much power do these 3 companies (BlackRock, Vanguard, and State Street) have? You will find out more in the part 2 of this show, coming next week. Sponsors: American Gold Exchange Our dealer for precious metals & the exclusive dealer of Real Power Family silver rounds (which we finally got in!!!). Get your first, or next bullion order from American Gold Exchange like we do. Tell them the Real Power Family sent you! Click on this link to get a FREE Starters Guide. Abolish Property Taxes in Ohio: https://reformpropertytax.com/ Our Links: www.RealPowerFamily.com Info@ClearSkyTrainer.com 833-Be-Do-Have (833-233-6428)

This week onThe Feds, we are joined by Meryl Nass, MD, founder and president of Door to Freedom, medical advisor to Children's Health Defense, and host on CHD TV. Dr. Nass provides an in-depth analysis of two concerning provisions in the 2025 House Appropriations Bill: Sections 453 and 507.  Section 453 prohibits funding for timely updates to product labels and safety recommendations, a critical issue given that successful lawsuits against chemical giant Bayer have often relied on labeling disputes. Dr. Nass explains the far-reaching implications of this rider for public health and safety. Additionally, Dr. Nass examines Section 507, which restricts government funding for the implementation or further study of a January 2025 EPA report. This report documented the toxic and carcinogenic effects of "forever chemicals" found in sewer sludge used as agricultural fertilizer, raising serious environmental and health concerns. Who in Congress is writing and supporting these sections? Why? What can YOU do as an American citizen? Tune in for this compelling discussion on critical policy issues impacting public safety and environmental health. This is an episode you won't want to miss! —Watch Dr. Nass' show regarding Section 507 (starts @ 36:30):https://live.childrenshealthdefense.org/chd-tv/shows/good-morning-chd/youre-employer-can-mandate-killing-you-poisoning-farmland/ Learn more about the history behind Section 453:https://merylnass.substack.com/p/will-congress-give-the-pesticide Read more about Section 507 and “forever chemicals:” https://merylnass.substack.com/p/sewer-sludge-was-deodorized-and-magically Dr. Nass' Organization:DoortoFreedom.org

Alexander Nübel war der entscheidende Mann bei Stuttgarts Zittersieg im Elfmeterschießen gegen Braunschweig. Bayer Leverkusen treibt den Kader-Umbruch weiter voran und der BVB verlängert mit Chefcoach Niko Kovač.

Die Bayern starten mit einem 6:0 gegen Leipzig - droht wieder Langeweile im Meisterrennen? Der Kader ist stark, aber schmal: Welche Ausfälle könnten entscheidend werden, und warum leiht der Rekordmeister derzeit nur? Bayern-Experte Mario Krischel ordnet ein. Zudem: Robert Arndt berichtet zur Basketball-EM, Niko Kovac verlängert und Bayer holt einen Ex-Real-Star.

[01:02:09] Conservatives Back Martial LawOpening monologue criticizes conservatives for supporting Trump's talk of deploying troops in U.S. cities, linking it to the Pentagon's long-term planning for urban control. [01:05:31] Prohibition, Cartels & TerrorComparison of alcohol prohibition to the drug war; warns that attacking Mexican cartels militarily could spark terrorism inside American cities and provide cover for martial law. [01:12:29] Election Rigging & GerrymanderingDiscussion of how both parties manipulate elections through gerrymandering and voting controls; frames Trump as a Pentagon puppet in a larger plan of urban militarization. [01:20:48] Conservatives Cheer MilitarizationChicago carjacking victim opposed National Guard deployment; conservatives attacked her online, showing how Trump has shifted the right to embrace authoritarian solutions. [01:29:46] Normalizing Martial LawAnalysis of how deploying troops in D.C. and other cities is “predictive programming” to normalize military presence and condition officials and citizens for broader martial law. [01:45:21] Democrats Only OppositionClosing reflections argue conservatives have abandoned constitutional limits, leaving only Democrats to oppose Trump's martial law plans—though they oppose for the wrong reasons, focusing only on partisan power. [02:19:39] Texas “Big Beautiful Map” & Election RiggingDiscussion of Texas Senate passing a gerrymandered redistricting bill, Trump pushing to ban mail-in ballots and voting machines, and how both parties manipulate elections. [02:32:18] CDC Launches Vaccine Injury ReviewCriticism of the CDC forming a group to investigate COVID vaccine injuries, framed as a whitewash to protect Trump's Operation Warp Speed and Big Pharma. [02:36:04] Genetic Code Injections & Aluminum RisksSegment highlights concerns over mRNA shots replicating uncontrollably and reviews studies linking aluminum adjuvants to asthma, autism, and SIDS. [02:43:09] Hypervaccination Horror StoriesPersonal accounts of children permanently damaged after “catch-up” vaccine schedules in custody battles; broader attack on CDC and medical industry dishonesty. [02:49:41] Bioweapon Narrative & Military OperationDiscussion frames COVID vaccination as a Pentagon/DARPA military operation, not medicine, with secrecy and top-secret clearances tied to bio-surveillance. [03:08:15] Bayer, Monsanto & Legal ImmunityDeep dive into Monsanto's history with Agent Orange, PCBs, Roundup, GMOs, and Bayer's Nazi past; warnings that Trump and RFK Jr. are paving the way for legal immunity for “Big Pest.” [03:30:29] Greenland Child Seizures & Parenting TestsCase of a Greenlandic mother losing her baby under “parenting competence tests,” framed as government overreach tied to globalist family-erasure agendas. [03:35:02] Miraculous Cardiac RecoveryTeen athlete suffers sudden cardiac arrest and survives after 30 minutes without a heartbeat, presented as both a vaccine injury suspicion and a story of prayer and divine healing. [03:38:13] Legacy of James DobsonReflection on the life and influence of James Dobson—praised for defending families but criticized for Zionism and naïve trust in government institutions. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

[01:02:09] Conservatives Back Martial LawOpening monologue criticizes conservatives for supporting Trump's talk of deploying troops in U.S. cities, linking it to the Pentagon's long-term planning for urban control. [01:05:31] Prohibition, Cartels & TerrorComparison of alcohol prohibition to the drug war; warns that attacking Mexican cartels militarily could spark terrorism inside American cities and provide cover for martial law. [01:12:29] Election Rigging & GerrymanderingDiscussion of how both parties manipulate elections through gerrymandering and voting controls; frames Trump as a Pentagon puppet in a larger plan of urban militarization. [01:20:48] Conservatives Cheer MilitarizationChicago carjacking victim opposed National Guard deployment; conservatives attacked her online, showing how Trump has shifted the right to embrace authoritarian solutions. [01:29:46] Normalizing Martial LawAnalysis of how deploying troops in D.C. and other cities is “predictive programming” to normalize military presence and condition officials and citizens for broader martial law. [01:45:21] Democrats Only OppositionClosing reflections argue conservatives have abandoned constitutional limits, leaving only Democrats to oppose Trump's martial law plans—though they oppose for the wrong reasons, focusing only on partisan power. [02:19:39] Texas “Big Beautiful Map” & Election RiggingDiscussion of Texas Senate passing a gerrymandered redistricting bill, Trump pushing to ban mail-in ballots and voting machines, and how both parties manipulate elections. [02:32:18] CDC Launches Vaccine Injury ReviewCriticism of the CDC forming a group to investigate COVID vaccine injuries, framed as a whitewash to protect Trump's Operation Warp Speed and Big Pharma. [02:36:04] Genetic Code Injections & Aluminum RisksSegment highlights concerns over mRNA shots replicating uncontrollably and reviews studies linking aluminum adjuvants to asthma, autism, and SIDS. [02:43:09] Hypervaccination Horror StoriesPersonal accounts of children permanently damaged after “catch-up” vaccine schedules in custody battles; broader attack on CDC and medical industry dishonesty. [02:49:41] Bioweapon Narrative & Military OperationDiscussion frames COVID vaccination as a Pentagon/DARPA military operation, not medicine, with secrecy and top-secret clearances tied to bio-surveillance. [03:08:15] Bayer, Monsanto & Legal ImmunityDeep dive into Monsanto's history with Agent Orange, PCBs, Roundup, GMOs, and Bayer's Nazi past; warnings that Trump and RFK Jr. are paving the way for legal immunity for “Big Pest.” [03:30:29] Greenland Child Seizures & Parenting TestsCase of a Greenlandic mother losing her baby under “parenting competence tests,” framed as government overreach tied to globalist family-erasure agendas. [03:35:02] Miraculous Cardiac RecoveryTeen athlete suffers sudden cardiac arrest and survives after 30 minutes without a heartbeat, presented as both a vaccine injury suspicion and a story of prayer and divine healing. [03:38:13] Legacy of James DobsonReflection on the life and influence of James Dobson—praised for defending families but criticized for Zionism and naïve trust in government institutions. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Sentera: https://sentera.com/Chandler Coop: https://www.chandlercoop.com/Today's episode is another installment in our Tech-Enabled Advisor series. The idea here is to better understand agtech through the lens of the BUYER and USER of that technology rather than just the entrepreneurs or investors behind it. I've received some super positive feedback about the return of this series. By talking to the buyers rather than the sellers of the tech, we got an unfiltered introduction to the technology and more importantly got to see HOW its used and the VALUE that it provides. To do this, I partner with a company and together we invite one of their customers onto the show. The catch is that they're not allowed to script these individuals or dictate what to say or edit it after it is recorded - it has to be real and unfiltered. So today's episode featuring Nick Einck of Chandler Coop is produced in partnership with Sentera. Sentera is a leading provider of remote imagery solutions. Their industry-leading cameras are compatible with most major drone platforms and enable farmers and crop scouts to efficiently capture high-resolution data. Their capabilities and FieldAgent software tools help farmers and agronomists assess plant-level health, identify stressors, and take action. Also their customized herbicide prescription, SMARTSCRIPT™ Weeds, can be delivered to sprayers with individual nozzle control.So drones equipped with Sentera technology fly over fields at high speeds and generate high-resolution images. The images are processed using proprietary deep learning algorithms to identify the exact location of specific weeds and generate a weed map. This map becomes a targeted prescription for how much product a farmer needs to load into their sprayer, saving money and minimizing waste. This past May, John Deere announced they were acquiring Sentera.So I'm very excited to partner with them for this episode, which is a fantastic deep dive into how innovative technology like this combined with something like See-and-Spray really changes the game.Some background on Nick before we dive in: Nick Einck is the Director of Agronomy at Chandler Co-op, a farmer-owned cooperative serving more than 900 customers and providing agronomic services across over 100,000 acres in southwest Minnesota. He began his career at Chandler as an intern and seed manager before spending nearly a decade with Monsanto and Bayer, gaining deep expertise in agronomy, product development, and grower engagement across the Midwest. Nick returned to Chandler in October 2024, bringing both retail and industry experience to help advance the co-op's agronomic strategy. Today, he leads a multi-location agronomy team focused on leveraging tech-enabled tools—like SmartScript™—to help growers make faster, more informed decisions and drive greater return from every acre.

Der erste Bundesliga-Samstag liegt hinter uns und hatte einige Überraschungen parat. Dortmund verzockt eine 3:1-Führung gegen St. Pauli. Can Uzun zaubert beim Eintrachts Kantersieg gegen Werder und Stuttgart und Leverkusen verpatzen den Auftakt.

Bayer schießt Leipzig ab und macht dem Rest der Liga schon wieder Angst! Beim HSV gibt es eine überraschende Torwart-Entscheidung und Gio Reyna steht vor einem Wechsel nach Gladbach.

“Savings is completely self-invented and pointless because it's separated from the real P&L." This assessment from Bayer Chief Procurement Officer Thomas Udesen captures the essence of what may be procurement's most radical transformation in decades. In this episode of “Buy: The Way...To Purposeful Procurement,” Thomas joins Philip Ideson and Rich Ham to discuss how one of the world's largest pharmaceutical companies abandoned traditional procurement metrics entirely, replacing “savings” with six C's that actually drive business outcomes: cost, cash, carbon, community, compliance, and continuity.  Thomas's approach defies conventional wisdom at every turn.  At Bayer, every employee can spend up to €50,000 without pre-approval – a level of transactional autonomy that would terrify most procurement organizations. Yet the results speak for themselves: increased responsibility, entrepreneurial thinking, and more strategic spend management decisions driven by transparency rather than control. The conversation reveals how procurement's obsession with “savings” has become a self-inflicted wound. Stakeholders roll their eyes when procurement leads with savings slides because the metrics mean nothing to them. Instead, Bayer measures real P&L impact through price index benchmarking and spend ratios that directly correlate to competitive performance.  In this episode, Thomas demonstrates that purposeful procurement isn't just theoretical; it's already happening. His parting challenge: procurement can be “the heartbeat of the change that is coming.”    Links: Thomas Udesen on LinkedIn Rich Ham on LinkedIn Learn more at FineTuneUs.com

Sermon delivered on the Tenth Sunday After Pentecost, 2025, in Richmond, Texas, by Rev. Tobias Bayer. Epistle: 1 Cor. 12, 2-11. Gospel: St. Luke 18, 9-14.

Sermon delivered on the Feast of the Assumption of the Blessed Virgin Mary, 2025, in Richmond, Texas, by Rev. Tobias Bayer. Epistle: Eccl. 29, 11-13. Gospel: St. Luke 10, 38-42.

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Holger Zschäpitz über ein Dekadenhoch in China, zwei frohe Botschaften bei Novo Nordisk und Rückenwind bei Windkraftaktien. Außerdem geht es um Rheinmetall, Hensoldt, Renk, Leonardo, Thales, Shanghai Composite, CSI 300, Tencent Music, Nio, Netease, Xiaomi, Tencent, Alibaba, BYD, JD, Vestas, Energiekontor, Siemens Energy, Nordex, SMA Solar, Bayer, GoodRX, Duolingo, Pro7Sat.1, Intel, Nvidia, Home Depot, Starbucks, Netlfix, Sixt, CTS Eventim, Nike, Spotify, Live Nation Entertainment, AMC, Amazon, Kyivstar, VEON. Und hier gibt es die Tickets zum Finance Summit am 17. September! https://veranstaltung.businessinsider.de/FinanceSummit Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

This episode covers: Cardiology This Week: A concise summary of recent studies Oral anticoagulation in atrial fibrillation: answers to frequent questions Smartwatch, heart rate and ECG Milestones: Lyon Diet Heart study Host: Emer Joyce Guests: Carlos Aguiar, Tim Chico, Paulus Kirchhof Want to watch that episode? Go to: https://esc365.escardio.org/event/1811 Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Paulus Kirchhof has declared to have potential conflicts of interest to report: partially supported by European Union MAESTRIA (grant agreement 965286), British Heart Foundation (AA/18/2/34218), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, grant numbers DZHK FKZ 81X2800182, 81Z0710116, and 81Z0710110), German Research Foundation (Ki 509167694), Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, and the Else-Kröner-Fresenius Foundation. Research support for basic, translational, and clinical research projects from German Research Foundation (DFG), European Union, British Heart Foundation, Leducq Foundation, Else-Kröner-Fresenius Foundation, Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, Medical Research Council (UK), and German Center for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last five years. Listed as inventor on two issued patents held by University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Tim Chico Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/1811   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this episode of One Dream, Leah Wilson and Bernadette Pajer dive deep into the urgent conversation about pesticides, food reform, and the corporations shaping our agricultural future. From Bayer and Monsanto's political influence to the hidden dangers in our food system, they unpack how liability shields, weak EPA oversight, and gaps in transparency put public health at risk. The discussion covers the health impacts of pesticide exposure—including cancer and reproductive issues—and reveals how consumer choice and political engagement can drive meaningful reform. Listeners will learn why regenerative agriculture offers hope, how to demand transparency in labeling, and why protecting our right to hold pesticide companies accountable is non-negotiable. This is more than a conversation—it's a rallying call for informed citizens to stand up for food safety, environmental health, and the future of farming. What You'll Learn in This Episode: How Bayer and Monsanto shape laws to protect the pesticide industry Why the term “pesticide” covers far more than herbicides The EPA's regulatory blind spots and their consequences Health risks tied to pesticide exposure How consumer awareness can change agricultural practices Why transparency in food labeling matters How political reform can protect public health and the environment The promise of regenerative agriculture as an alternative Why we must fight against pesticide liability shields Resources Mentioned: Find all of Stand for Health Freedom's resources on the pesticide issue, here. One Dream on Instagram: @onedream.podcast — DM us your detox questions Follow The One Dream Podcast:

Sermon delivered on the Feast of St. Lawrence, 2025, and the Ninth Sunday After Pentecost, in Harrisburg, Pennsylvania, by Rev. Tobias Bayer. Epistle: 2 Cor. 9, 6-10. Gospel: St. John 12, 24-26.

https://www.youtube.com/watch?v=Gm7PICSLkhc Podcast audio: In this episode of The Ayn Rand Institute Podcast, Ben Bayer and Agustina Vergara Cid take a wide-ranging look at abortion bans since the overturning of Roe v. Wade, examining their destructive effects on the lives and freedoms of women and medical professionals. Among the topics covered: Ayn Rand's distinctive defense of abortion rights; How abortion bans have impaired women's lives; How anti-abortion laws impose arbitrary constraints against sound medical judgment; The unfortunate rise of pregnancy-related prosecutions; How abortion restrictions jeopardize doctors' freedom and careers; Why signs of resistance show abortion bans can be reversed; Evidence that the anti-abortion movement is motivated by a dark anti-sex agenda. Recommended in this podcast are the Ayn Rand Lexicon entry on Abortion, Bayer's book “Why the Right to Abortion Is Sacrosanct,” and his article “The Dark Form of Control Even Anti-Abortion ‘Moderates' Want.” The podcast was recorded on July 28, 2025 and posted on August 9, 2025. Listen and subscribe wherever you get your podcasts. Watch archived podcasts here.

Häufige Dürre, neue Schädlinge - der Klimawandel belastet die Landwirtschaft. IQ - Autorin Renate Ell fragt in dieser Podcast Folge: Können klimafitte Sorten, mit neuer Gentechnik schnell gezüchtet, solche Probleme lösen? Oder sind die Risiken dieser neuen Technologie noch nicht einschätzbar? Wie kann die Landwirtschaft zukunftsfähig werden? CREDITS Autorin/Sprecherin: Renate Ell Technik: Maik Siegle / mars13 Redaktion: Sarah Bioly Unsere GesprächspartnerInnen: Sean Mayes Wricha Tyagi, International Crops Research Institute for the Semi-Arid Tropics (ICRISAT) Hyderabad, Indien
https://www.icrisat.org/ Prof. Dr. Chris-Carolin Schön, Lehrstuhl Pflanzen­züchtung, Technische Universität München
 https://www.professoren.tum.de/schoen-chris-carolin 
 Dr. Luise Zühl, Bundesamt für Naturschutz, Bonn
https://www.mpipz.mpg.de/5422433/luise-zuehl
 Prof. Dr. Matin Qaim, Leiter des Zentrums für Entwicklungsforschung an der Universität Bonn; https://www.zef.de Wir freuen uns über Post von Euch: WhatsApp (https://wa.me/491746744240) oder iq@br.de Falls Euch der IQ-Podcast gefällt, freuen wir uns über eine gute Bewertung, einen freundlichen Kommentar und ein Abo. Zum Weiterlesen, Weiterhören und Quellen: "Gelinsky-Liste", jährlich aktualisiert und vom schweizer Bundesamt für Umwelt (BAFU) veröffentlicht
 https://www.bafu.admin.ch/bafu/de/home.html Bayer. Staatsmininsterium f Umwelt und Verbraucherschutz Starke Pflanzen im Klimawandel, Projektverbund in Bayern
https://www.stmuv.bayern.de/themen/klimaschutz/forschung/bayklimafit/bayklimafit2.htm Europäische Behörde für Lebensmittelsicherheit: neue genomische Verfahren
https://www.efsa.europa.eu/de/topics/new-genomic-techniques 
 Und wenn Ihr unseren Podcast unterstützen wollt, empfehlt uns gerne weiter! IQ verpasst? Hier könnt ihr die letzten Folgen hören: https://1.ard.de/IQWissenschaft

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Eli Lilly is facing significant drug pricing pressure, with issues ranging from the pricing of their weight loss pill Orfoglipron to market battles with competitors like Novo Nordisk. Despite the challenges, Lilly's executives see opportunities for their products in the real world. Jazz Pharmaceuticals received FDA approval for Dordaviprone, making it the first new treatment for an ultra-rare brain tumor. In other news, Sarepta beat Q2 estimates despite not holding an investor call, and Trilink Biotechnologies is offering process development services for nucleic acid therapeutic development. Lotte Biologics is expanding its global CDMO operations, while a big pharma-backed mRNA startup raised $153 million in funding. Novo Nordisk's new CEO is focusing on obesity and diabetes, Pfizer is in talks with Trump on most favored nation drug pricing, and Bayer expects more layoffs. These developments in the pharma and biotech world showcase the ongoing challenges and opportunities in the industry. Stay tuned for more updates on the latest news and trends in this rapidly evolving sector.

Roberto Moro, analista de apta negocios, comenta la actualidad del mercado con una visión optimista sobre el comportamiento del Ibex 35. Señala que “el índice español se encuentra en una situación de subida libre, ya que, si se observa el gráfico con dividendos, está superando su anterior máximo histórico en torno a un 3,5%”. En cuanto a valores internacionales, pone el foco en Apple, que acaba de romper una resistencia importante, una zona que en tres ocasiones anteriores había frenado el avance del precio. Para Roberto Moro, “si la acción logra cerrar por encima del nivel del día anterior, se convierte en una opción muy interesante para retomar la senda alcista y buscar niveles de máximos históricos”. En contraste, advierte sobre Bayer, que se mantiene en una estructura claramente bajista. “Todo lo que sea permanecer por debajo de la zona de los 35 euros supone mantener la continuidad bajista”, afirma. De vuelta al mercado español, el analista destaca al sector bancario como uno de los más fuertes del momento, aunque se muestra cauto con BBVA y Sabadell. También señala a Merlin Properties y Solaria como compañías a seguir de cerca.

Dr. Sumanta (Monty) Pal and Dr. Kimmie Ng discuss the disturbing rise of early-onset gastrointestinal cancers, the unique challenges faced by younger patients, and key research that is shedding light on potential drivers of early diagnoses in colorectal cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello, everyone. I'm Dr. Monty Pal, and I'm a medical oncologist and professor and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. I'm really delighted to welcome you all to the ASCO Daily News Podcast as the show's new host. I'll be bringing you discussions with leaders in the oncology space on a variety of topics. I've been working hard with the ASCO team on picking the ideal topics to bring to you, and I'm really delighted to introduce my first guest, a dear friend, Dr. Kimmie Ng, to discuss this huge problem that we're seeing nowadays of early-onset GI cancers. Dr. Ng is the associate chief of the Division of Gastrointestinal Oncology at the Dana-Farber Cancer Institute, and she's an associate professor of medicine at Harvard Medical School in Boston. She serves as co-director of the Colon and Rectal Cancer Program. She's also the founding director of the Young-Onset Colorectal Cancer Center at Dana-Farber. I'm sure we'll talk a little bit about that today.  Just to note, our full disclosures are available in the transcript of this episode.  Dr Ng, it's so great to have you on the podcast. Thanks so much for joining us. Dr. Kimmie Ng: Thank you so much for having me. It's great to be here. Dr. Sumanta (Monty) Pal: I'm going to refer to you as Kimmie, if you don't mind, for the rest of the podcast here. Please, we'll go by first names, if you don't mind.  Your research has really done so much to help improve our understanding of early-onset GI cancers. You've done a lot of work to increase awareness in this space. I don't think there's a couple of months that passes by when I don't see you on television on Good Morning America or other shows really broadcasting this really critical message. I think there's a certain sensitivity that we all have to this issue, right? I mean, because receiving a cancer diagnosis at any age is very challenging, but I'm sure that young patients who face a colorectal cancer diagnosis have some very unique challenges. Could you give us a sense of some of those? Dr. Kimmie Ng: I think the other reason why so many people are interested in this and feel touched by this is that it's not just gastrointestinal cancers that are increasing in young people, but actually a multitude of different cancers have been rising in young individuals. And while it is difficult at any age to receive a cancer diagnosis, we do all know that young people getting a diagnosis like this do face unique challenges. Studies have shown that over 80% have children under the age of 18 when they are diagnosed with colorectal cancer, for example, under the age of 50. And many experience career and education disruptions. They are in what we call the ‘sandwich generation,' where they're not only taking care of young families or starting to think about starting a young family, but they're also taking care of elderly parents. So it's just a very busy stage of life, and to then be facing a usually terminal cancer diagnosis, it is extremely challenging. The other factors that we've seen that seem to be unique or more prevalent in young patients is that there are higher levels of psychosocial distress, depression, and anxiety, and a majority of patients do need medical attention and treatment for those things, whether it's medication treatment or whether it's counseling or support from psychosocial oncologists. And so the other big issue is fertility. We know that so many of the treatments that these young patients receive do permanently and negatively impact fertility. And for a person who is young, who may still be trying to expand their family or again start a family, it is very important that these young patients do receive counseling about fertility preservation prior to starting treatment. Dr. Sumanta (Monty) Pal: You know, it's so interesting you bring this up, and I think about a patient who's in their 40s diagnosed with this disease. They're in the same demographic as I am, as you are. You know, I'm 44 years old, and you know, I'm thinking about my 11- and 12-year-old and my aging parents, right? I mean, the dilemmas that you highlighted are precisely what I'm facing in life, and it's so true, right? If I had to take my day-to-day and superimpose on that a colorectal cancer diagnosis, it would just be problematic in so many spheres, so many spheres. Dr. Kimmie Ng: Absolutely. And because we did think going into this, starting our Young-Onset Colorectal Cancer Center, that these patients will need unique supports, we did conduct a qualitative study and held some focus groups of young-onset colorectal cancer patients as well as their caregivers. And we really identified four primary themes that I think reflect a lot of the experience of patients with cancer, no matter what type of cancer when they're diagnosed young. And the first is the need, feeling overwhelmed by the healthcare system, and the need for patient navigation. As we know, a lot of these patients are previously healthy before they're facing this very serious diagnosis. The second is the need for peer-to-peer support, where they really value connecting with other young patients going through a similar experience. The third, we talked about already, the need for kind of formal psychosocial support in the form of psychosocial oncologists or psychiatrists or social workers. And the last is an interest in research. They are really very invested in getting germline genetic testing as well as somatic genomic profiling to help guide their therapy. Dr. Sumanta (Monty) Pal: That's really encouraging to hear that they themselves are interested in participating in research. I mean, obviously, that's a great way to move the field forward. I view your area of work here as being such a vexing problem because no matter what way you slice it, young-onset colorectal cancer still remains a relatively small proportion of all diagnoses. So how do you go about studying this phenomenon? I mean, it must be challenging to really sort of investigate underlying causes when ostensibly this is still a small piece of the pie. Dr. Kimmie Ng: That is such a great question and is one of the challenges me and my research team think about every single day. As you mentioned, one of the major barriers is that although these cancers are rising in young people, the absolute number of patients being diagnosed is still relatively small, and if it's going to take large scale epidemiologic studies to really understand, for example, what the dietary and lifestyle risk factors are, you need a considerable number of patients in order to have enough power to reach definitive conclusions.  And so this is where it is so important to collaborate. Any single institution is not going to see enough young-onset patients with colorectal cancer to be able to do this work on their own. And so I have really been intent on establishing an international prospective cohort study of patients with young-onset colorectal cancer so that we can increase the numbers of patients we partner with to try to answer these questions, but also so that we can study this on a global scale, because unfortunately this is not something that's just plaguing the United States. It is actually happening in multiple countries around the world. So that is one barrier.  The second, I would say, is that we think it's early life exposures to whatever environmental factor it is that's causing the rise that is likely contributing the most. And so if you imagine how difficult it would be to start studying individuals from when they're children through adolescence, through adulthood, and then all the way until a cancer diagnosis is obtained, a study like that would take too long, would cost too much, and really wouldn't be feasible. So we need to think of alternative ways to really try and answer this question of what is driving this rise in young-onset colorectal cancer. Dr. Sumanta (Monty) Pal: Honestly, Kimmie, this seems like almost an unfair question in the context of what you just mentioned, the challenges in terms of ascertaining causality, right? I'll tell you, I cheated a little bit ahead of this podcast. Kimmie and I had dinner together in Los Angeles a couple months ago. She came out to deliver a Presidential Lectureship at City of Hope. We were delighted to have her. And we did have a couple of thoughts exchanged over potential drivers of these early diagnoses, leaning on perhaps one of the things that you and I are both interested in, the microbiome. But amongst all these things, vitamin D, microbiome, etc., and I won't hold you to this, do you have at least a general sense of what might be contributing to this early-onset phenomenon? Dr. Kimmie Ng: Yeah, as we talked about during my visit there to City of Hope, we do hypothesize that it is a complex interaction between our exposome, which is everything we are exposed to in our environment, which does include diet and lifestyle factors, interacting with host immunity and antitumor immunity, and as well as the microbiome and shaping the composition and diversity of the gut microbiome that are likely interacting to increase susceptibility to colorectal cancer at a younger age. And I will say one of the biggest discoveries, if you will, about what might be driving young-onset colorectal cancer was published a few months ago in Nature. And that paper identified a specific mutational signature caused by the genotoxin colibactin, which is often produced by an organism called pks+ E. coli, as being much more prevalent in younger patients with colorectal cancer than older patients. And so while it doesn't explain necessarily all of young-onset colorectal cancer and why it's rising, it does give us a clue that the microbiome is likely very important in perhaps why this is rising in young people. Dr. Sumanta (Monty) Pal: After you mentioned it, I went back and dove deep into that paper. I was fascinated, fascinated by the content there. And this is just a massive exploration across thousands of patients worldwide. So, I mean, if there is a way to get at least some hint of what's driving this phenomenon, I suppose that's it. So thank you for pointing me in the direction of that manuscript. Now that we've addressed the issue of diagnosis, if we could just, you know, verge on the topic of treatment, right? And this is something that I struggle with. When I have my young patients with kidney cancer, I don't know necessarily that my treatment paradigm changes a whole heck of a lot. I guess what I will say is I might be a little bit more aggressive about concepts like definitive management with surgery. I suppose perhaps their treatment tolerance is a little bit higher. But tell us about the setting of young-onset colorectal cancer. Is the philosophy any different in terms of the actual sort of management of these patients? Dr. Kimmie Ng: That's a great question, and actually I was honored to participate in the first international consensus guidelines group to try to come up with uniform recommendations for how to treat young patients with colorectal cancer. And you know, the overall consensus is just as you said, the medical care of these young patients right now is really not that much different than that of an older patient with colorectal cancer. There are a couple of distinctions. One is that all young patients should get germline genetic testing, given that there is a higher prevalence of pathogenic germline variants when you are diagnosed at a young age. And the second is what we've already talked about, which is that all young patients should be referred for counseling about fertility preservation prior to starting treatment. But otherwise, the chemotherapy regimens recommended, you know, surgery, radiation, all of that seems very similar to older patients. I will say that because most of our young patients with colorectal cancer are diagnosed with left-sided cancers, including rectal cancers, where some of the treatment may be morbid and result in lifelong complications, we do consider de-escalation of therapy and try to consider the long-term implications when it's safe to do so and won't compromise outcomes. The other concerning thing is that younger patients don't necessarily have a better prognosis than older patients. And multiple studies have shown this, that even though we both often treat younger patients more aggressively – they more often receive multi-agent chemotherapy, and more often undergo surgery and radiation – their survival is not necessarily correspondingly better than an older patient with colorectal cancer. So that suggests to us that maybe these cancers are indeed biologically different and perhaps more aggressive or perhaps less responsive to treatment. And so that is some of the focus of our research too, to understand what is actually different about these cancers and how they respond to treatment. Dr. Sumanta (Monty) Pal: It's such a paradox, isn't it, right? Because you just brought this to my mind. I guess on the one hand, our younger patients may be able to tolerate perhaps a greater amount of chemotherapy, targeted therapy, etc. But you're absolutely right. I mean, they do sort of have these lingering issues with side effects that may persist for much longer than the 80- or 90-year-old that we're treating in the clinic. I mean, these tend to be sort of lifelong consequences and sequelae that they're dealing with. So that really does evolve to be a challenge. You've kind of changed my mindset there a little bit. Dr. Kimmie Ng: Yeah, I do think survivorship issues and long-term complications of therapy do need to be considered, especially for a young person who we hope will live a very, very long time. And so part of the work that our Young-Onset Colorectal Cancer Center is doing, we are participating in a pilot navigation study where we navigate patients to survivorship earlier than we typically would, perhaps, for an older patient. And that's so we can get a head start on addressing some of those potential complications of therapy and hopefully mitigate them so that they don't become an issue long term. Dr. Sumanta (Monty) Pal: Do you think there's a role for de-escalation studies formally in these young populations of patients? Dr. Kimmie Ng: I think de-escalation studies are important overall, and specifically for locally advanced rectal cancer, which again is one of the most common types of colorectal cancer diagnosed in our young patients, there are certain populations that may be able to forgo the radiation treatment to the pelvis, for example, and there's more and more patients who now may become candidates for non-operative management where they may not necessarily need to have their rectal cancer surgically removed. And elimination potentially of both of those modalities of treatment can really avoid some of the most serious and morbid complications that often occur with these treatments. Dr. Sumanta (Monty) Pal: Really interesting. Now, this is not and will never be a political podcast, but you know, obviously we're dealing with the consequences of changes on funding and so forth that have evolved over time. And I think it's worth sort of speculating how the landscape of research may change on account of that. Could you comment perhaps a little bit on how some of the funding cuts that we've seen recently at the NIH might affect the body of work that you're so integrally involved in? Dr. Kimmie Ng: I am honestly very worried about the current funding environment. Colorectal cancer is the third most commonly diagnosed cancer among men and women in the United States and globally, and when you combine men and women together, the second leading cause of cancer death. But proportionally, we receive much less funding for colorectal cancer compared to other cancer types. And my thoughts have always been that perhaps this is because there is this stigma around colorectal cancer and maybe some of the symptoms associated with colorectal cancer. And so on top of that, to have additional challenges in obtaining funding, I worry what it will do to the pace of progress for especially young patients with this disease. Also, because of some new stipulations that perhaps international collaborations are being discouraged, I also worry about that aspect of it because young-onset colorectal cancer and gastrointestinal cancers in general is a global phenomenon happening in multiple countries around the world. And if we are to understand what the environmental factors are affecting the different rates of rise in these different countries, we do so much need that international collaboration. So yes, I am worried, and I do hope that conversations like this will spark an awareness of the need for more funding and continued funding into this disease. Dr. Sumanta (Monty) Pal: I will say that, and the audience can't see this because this is an audio program, but I'm wearing my Southwest Oncology shirt here, a SWOG, and it's one of the National Cancer Institute-funded cooperative groups. And you know, I was recently dismayed to find that, you know, funding got cut for international collaborations and enrollment in South America and Latin America. And this was traditionally actually a mainstay of our enrollment for many trials, including trials in rare cancers that present themselves in younger patients in the GU space. So, I completely agree with you. We've got to do something to address this funding issue to make sure that this body of work, both yours and mine, continues, without a doubt. Kimmie, this has been a delightful conversation. I really want to thank you for, you know, leading the charge in the young-onset colorectal cancer space, and you've done so much tremendous work here. Dr. Kimmie Ng: Thank you for having me. Dr. Sumanta (Monty) Pal: If you value the insights that you hear on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. And again, thank you for joining us today. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:   Dr. Sumanta (Monty) Pal @montypal Dr. Kimmie Ng @KimmieNgMD Follow ASCO on social media:    @ASCO on Twitter   ASCO on Bluesky  ASCO on Facebook    ASCO on LinkedIn    Disclosures:   Dr. Sumanta (Monty) Pal: Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis Dr. Kimmie Ng: Honoraria: Seagen, GlaxoSmithKline Consulting or Advisory Role: CytomX Therapeutics, Jazz Pharmaceuticals, Revolution Medicines, Abbvie, Bayer, Pfizer, Agenus, Johnson & Johnson/Janssen, Etiome, AstraZeneca Research Funding (Inst.): Pharmavite, Janssen Other Relationship: JAMA

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über einen smarten Abo-Trick der New York Times, Margen-Flaute bei AirBnB und Hoffnung auf ein serienreifes Happy End bei Disney. Außerdem geht es um Apple, Amazon, Tesla, Nvidia, Intel, McDonald's, Uber, Bayer, Siemens Energy, Zalando, Beiersdorf, Vonovia, TAG, Aroundtown, Opendoor Technologies, Snap, Lucid, AMD, Super Micro, Shopify, Match Group, Bumble, Softbank, OpenAI, Novo Nordisk und Solactive China Humanoid Robotics Index. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Esto es El Brieff, tu resumen conciso de las noticias clave. En México, la controversia por el viaje de AMLO Beltrán a Japón y la postura de Sheinbaum marcan la semana, junto a nuevas inversiones de Blackstone y el impulso a la IA con AWS. EE. UU. sanciona al Cártel del Noreste, incluyendo a "El Makabelico". Trump genera revuelo con aranceles a India y chips, además de planes de reunirse con Putin y Zelensky. China usa IA para influir en Hong Kong y Taiwán. Uber enfrenta denuncias de agresión sexual, mientras Apple anuncia una gran inversión. Bayer recorta empleos, Glencore se queda en Londres, y Disney y NFL cierran un acuerdo millonario. Italia aprueba el ambicioso puente a Sicilia. Recibe gratis nuestro newsletter con las noticias más importantes del día.Si te interesa una mención en El Brieff, escríbenos a arturo@brieffy.com Hosted on Acast. See acast.com/privacy for more information.

Unser Partner Scalable Capital ist der einzige Broker, den du brauchst. Inklusive Trading-Flatrate, Zinsen und Portfolio-Analysen. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Apple mag Trump. Indien nicht. New York Times kann Werbung. Shopify kann Nummer 1 sein. Snap kann das nicht. Zalando & Beiersdorf leiden unter Wirtschaft. Bayer leidet unter Wirtz. Disney hat Deals aber zu wenig Zuschauer. McDonald's & Match wachsen wieder. Coinbase (WKN: A2QP7J) hat weniger Handelsvolumen als der Gesamtmarkt. Aber vielleicht das geilere Stablecoin-Biz als Circle (WKN: A417ZL). Strategy (WKN: 722713) verkauft Aktien und kauft Bitcoins. Aber wie lange noch? Diesen Podcast vom 07.08.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Novo Nordisk's new CEO, Maziar Mike Doustdar, is focusing on developing more drugs for obesity and diabetes while trimming the company's pipeline. The Department of Health and Human Services is terminating around $500 million in contracts for mRNA vaccine development, affecting companies like Moderna and Pfizer. Chinese biotechs are turning to big pharma for partnerships to survive, while Trilink Biotechnologies offers process development services for nucleic acid therapeutic development. Other top stories include biopharma CEOs being pulled into policy discussions, Bayer expecting more layoffs, and Trump threatening high tariffs on pharmaceuticals. The industry is also seeing investments in future technologies and strategies, such as AI for real-world research and integrated supply chain strategies for pharma manufacturing.Big pharma is providing support to struggling Chinese biotech companies by out-licensing drugs to multinational corporations. The recent increase in deals highlights the potential for partnerships with biotechs in the region. Biopharma CEOs are facing policy questions from tariffs to drug pricing, impacting their second quarter earnings calls. AI can help pharmaceutical companies adapt to policy pressures in the regulatory environment. Big pharmas are investing in incubators and venture funds to uncover scientific trends and determine future focus points. Pfizer's CEO is in contact with the President over drug pricing policies, while Moderna is focused on R&D partnerships rather than mergers and acquisitions. Novo's new CEO is emphasizing execution in obesity and diabetes research while trimming their pipeline. Biontech is committing to infectious diseases amid concerns over vaccine demand. Trump's threat of high pharma tariffs, a surge in July layoffs, and legal battles between Moderna, Pfizer, and Biontech are also making headlines. Events on AI for real-world research and integrated supply chain strategies for pharma manufacturing are upcoming, along with job opportunities in biostatistics, manufacturing, and publications.

Dr. Adam Kinnaird of the University of Alberta joins Dr. Aly-Khan Lalani and Dr. Christopher Wallis to explore the evolution of prostate cancer diagnostics, from the limitations of transrectal ultrasound to the rise of MRI and micro-ultrasound. They unpack key trials, discuss real-world challenges like long MRI wait times in Canada, and examine how micro-ultrasound offers a scalable, point-of-care solution. This can't-miss episode charts a path toward faster and more accurate prostate cancer care.This podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

Tom Preston, co-author of COACHING POWER, is the founder of The Preston Associates, one of the world's premier executive coaching firms. With decades of experience coaching leaders across industries and geographies, he has helped organizations achieve extraordinary outcomes. A former private equity executive and bestselling author of Coach Yourself to Success, he brings deep insights and practical wisdom to his work.Luciana Nuñez, co-author of COACHING POWER, is an accomplished executive coach and former CEO with more than 20 years of leadership experience at Fortune 500 companies, including Bayer, Danone, and Roche. She blends her strategic expertise with a passion for mentoring, serving as a board member, investor, and advisor to entrepreneurs and executives worldwide.

APAC stocks traded somewhat mixed following the subdued handover from Wall St post-ISM services.European equity futures indicate a positive cash market open with Euro Stoxx 50 future up 0.3% after the cash market closed with gains of 0.1%.DXY is flat, EUR/USD remains on a 1.15 handle and capped by its 200DMA, and antipodeans marginally lead.RBI kept the Repurchase Rate unchanged at 5.50%, as expected, and maintained a neutral stance.Looking ahead, highlights include German Industrial Orders (Jun), EZ Construction PMIs (Jul), EZ Retail Sales (Jun), Italian Industrial Output, Fed's Collins, Cook and Daly, Supply from Germany & US.Earnings from Airbnb, Lyft, Uber, Shopify, Walt Disney, McDonald's, Novo Nordisk, Siemens Energy, Commerzbank, Bayer, Fresenius, Beiersdorf, ABN AMRO & Glencore.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Tune in as Isabel and Jade analyse the standout moments from EMJ GOLD's guests this season, uncovering the challenges and opportunities shaping today's pharmaceutical industry. From self-advocacy at work and the future of personalised medicine to disease awareness, market access and making your marketing efforts stand out – they explore the season's core themes, all backed by the latest industry data. Watch our featured guest's full episodes: GSK's Dheepa Chari on the evolving sphere of scientific communication Yacin Marzouki on disrupting the traditional omnichannel model BMS' Anita Gandhi on a decade of change in hematology Pfizer's Richard Maughan on the future of access in the UK GSK's Matt Mortimer-Ryan on behaviour-led pharma marketing Chiesi's Shish Patel on COPD, the climate and improving care AbbVie's Dr Daejin Abidoye on community and compassion in cancer care Bayer's Dr Joana Reis on the promise of AI in breast cancer

Die VW-Tochter Audi erwägt, ein neues Werk in Tennessee, USA, zu bauen, während Bayer trotz positiver Prognosen mit einem sinkenden Aktienkurs zu kämpfen hat.

Zen Honeycutt, founder and executive director of Moms Across America and author of “Unstoppable: Transforming Sickness and Struggle into Triumph, Empowerment and a Celebration of Community,” details the origins and mission of the nonprofit organization aimed at transforming the food supply and improving health by reducing chemicals in food, water, and air. Highlighting the impact of grassroots activism, Honeycutt illustrates how the organization's initiatives have driven significant awareness and policy changes, including advances in organic food consumption and labeling. She also touches on the challenges posed by government and corporate influences, advocating for policies that put children's health and safety first. Honeycutt emphasizes the importance of individual actions and community involvement in creating a healthier future.

Dr. Hoffman continues his conversation with Zen Honeycutt, founder and executive director of Moms Across America and author of “Unstoppable: Transforming Sickness and Struggle into Triumph, Empowerment and a Celebration of Community.” 

Today's guest is Patricio La Rosa, Head of End-to-End Decision Science in Seed Production Innovation at Bayer Crop Science. Patricio joins the AI in Business podcast to explore how AI is transforming the clinical trial lifecycle, from biomarker discovery to long-term patient engagement. Drawing on his academic expertise, Patricio explains how AI-powered systems such as metagenomics, NLP, and multimodal sensing are helping researchers identify robust biomarkers and predict patient outcomes more effectively. He emphasizes the importance of reproducibility, effect traceability, and the scalability of sensing modalities from trial design to clinical practice. Patricio's discussion with Emerj Editorial Director Matthew DeMello then shifts to the human element — how to build trust with patients, improve adherence, and balance transparency with innovation. With deep insight and clarity, Patricio challenges industry leaders to rethink clinical trials not just as scientific protocols—but as collaborative, data-driven partnerships with future customers. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

The ouster of Vinay Prasad after three months running FDA's Center for Biologics Evaluation and Research could signal a reset is ahead for CBER. On the latest BioCentury This Week podcast, BioCentury's analysts discuss what the latest shakeup at the regulatory agency says about what's next for FDA.The analysts also assess two leading European pharmas: obesity and diabetes company Novo Nordisk, which named a new CEO last week while cutting its 2025 forecast, and Bayer, which is gearing up for launches and is revamping its pipeline to restart growth. Finally, they discuss the promising clinical data that's reviving interest in masking technologies that conditionally activate biologics.View full story: https://www.biocentury.com/article/656649#FDA #CBER #NovoNordisk #ObesityDrugs #Bayer01:05 - Prasad's Ouster14:59 - Novo's New CEO21:14 - Bayer's Growth Strategy26:05 - Masked BiologicsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In this compelling follow-up episode, we take a deep dive into one of the most pervasive and controversial chemicals in our environment today—glyphosate, the active ingredient in Roundup. Building on previous discussions about microplastics and PFAS, we explore what glyphosate is, how it came to dominate farming practices, and its far-reaching impacts on human health.What You'll Learn in This Episode:History & Background:Discover how glyphosate was first synthesized, the story behind its widespread use in agriculture, and the rise of Monsanto (now owned by Bayer).Health Impacts:We detail the alarming health concerns associated with glyphosate exposure, including links to cancer (such as lymphoma and other tumor types), hormone disruption, mitochondrial dysfunction, oxidative stress, and compromised detoxification systems.Why Is Glyphosate Everywhere?Find out which crops and common foods are most often contaminated—think soy, corn, wheat, barley, oats, canola oil, beans, strawberries, and more—and why even everyday foods could be placing your health at risk.Lawsuits, Regulation, and Liability:Get the latest on bans in other countries, pending U.S. legislative changes (like the 'chemical liability shield'), and the massive legal battles against glyphosate manufacturers.How it Affects the Body:Learn the insidious ways glyphosate disrupts the gut microbiome, depletes essential amino acids, interferes with energy production, and damages DNA and cell membranes.Detection and Testing:We share how glyphosate exposure is measured (including available urine tests) and what high exposure could mean for you and your family.Taking Action:Practical tips for reducing your exposure:Why going organic makes a real difference—especially for the “dirty dozen” foodsHow to support your body's natural detox pathwaysThe importance of water and food filtration, bowel health, and nutrients like glutathioneEmpowering Your Health Decisions:We emphasize taking proactive steps, advocating for change, and becoming your own health advocate.Takeaway:Glyphosate exposure is likely much more common than most people think—even detectable in over 90% of pregnant women in the U.S. We urge listeners to stay informed, support their detoxification systems, and push for safer farming and food practices.Links & Resources:For more information on glyphosate testing, look into Mosaic Labs and other organic acid test providers.Search up the “Dirty Dozen” list of produce most likely to contain pesticides.For future episodes on water filtration and detox strategies, stay tuned!Ready to take charge of your health? Have questions or want us to tackle a future topic? Reach out to the Health, Wealth and Ultimate Self team. Remember: this episode is for educational purposes only and is not medical advice—contact your provider for personal recommendations.Subscribe, share, and empower yourself for better health—one step at a time!

This new chemical immunity bill pretends to support farmers while legally granting immunity from lawsuits against harm to the producers of pesticides, herbicides, fungicides, and insecticides. There have been billions of dollars in settlements from glyphosate, and there are currently 165,000 active cancer lawsuits against the producer. If this immunity bill passes, all of these lawsuits will go away!Section 453 of the bill grants legal immunity to domestic and foreign chemical producers. Future failure-to-warn pesticide lawsuits would be dismissed. We often trust chemicals and drugs that are considered safe and effective, only to find out that they are actually deadly. This is due to a loophole allowing drug and chemical companies to keep negative safety studies confidential and unpublished. The Modern Ag Alliance is a “front group” created by Bayer. They create grassroots movements to make it appear that most people agree that glyphosate is a critical farming tool. They claim that it's safe and vital to secure our food supply. Groups within the WHO have labeled glyphosate as a probable carcinogen for humans, and many people have won cancer lawsuits against the manufacturer. Despite the evidence, chemical companies are taking a food security stance, claiming we will starve without glyphosate.Kelly Ryerson explains that if these companies achieve legal immunity, they will be allowed to continue to use chemicals that have been shown to cause health problems like Parkinson's, cancer, ALS, infertility, and more, with no consequences! This agricultural chemical liability shield will be virtually impossible to reverse if passed.To fight back against the pesticide legal immunity bill, contact your state senators and tell them you do not support any language granting legal immunity to chemical companies!Dr. Eric Berg DC Bio:Dr. Berg, age 60, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the Director of Dr. Berg Nutritionals and author of the best-selling book The Healthy Keto Plan. He no longer practices, but focuses on health education through social media.

Aktien hören ist gut. Aktien kaufen ist besser. Bei unserem Partner Scalable Capital geht's unbegrenzt per Trading-Flatrate oder regelmäßig per Sparplan. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Trump schockt mit Zöllen und Arbeitsmarkt. Berkshire Hathaway verkauft und verkauft. Bayer ist endlich mal High-Performer, genau wie Innoscience. Watches of Switzerland, Cancom, Bechtle und Daimler Truck können das nicht behaupten. Wie geht's eigentlich Linde (WKN: A3D7VW), seitdem's nicht mehr im DAX ist? Fantastisch. Investoren haben keinen Bock auf Excel. Clearwater Analytics (WKN: A3C32W) ist die Lösung. Diesen Podcast vom 04.08.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Host: Emer Joyce Guest: Christian Hassager Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1812?resource=interview  Want to watch the full episode? Go to: https://esc365.escardio.org/event/1812   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers:  Cardiology this Week: A concise summary of recent studies Atrial fibrillation in heart failure Temperature management following cardiac arrest Statistics Made Easy: Collider bias Host: Emer Joyce Guests: Carlos Aguiar, Christian Hassager, Theresa McDonagh Want to watch that episode? Go to: https://esc365.escardio.org/event/1812 Want to watch that extended interview on temperature management following cardiac arrest? Go to: https://esc365.escardio.org/event/1812?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Welcome back to The Birth Lounge Podcast—where we challenge the status quo, ask the questions the system hopes you won't, and take your family's health seriously (without fear-mongering or fluff). In today's episode, I'm sitting down with Kelly Ryerson, co-executive director of American ReGen and founder of Glyphosate Facts. With degrees from Dartmouth and Stanford, Kelly brings the heat and the receipts on one of the most important (and honestly, infuriating) topics in modern health: glyphosate. Yup, that's the same chemical in Roundup—the most widely used pesticide on Earth. And spoiler alert: it's likely in your pantry right now. We dive deep into: The truth about glyphosate's impact on your gut, your mental health, and your baby's long-term development How companies like Monsanto (now Bayer) are still running the show—and why we can't trust the system to keep us safe What you can do today to reduce your exposure (hello, water filters + better food choices) Why baby food is a big red flag (yes, even organic) What's actually happening on farms, and how regenerative practices can change the game This episode is part science, part scandal, and fully focused on helping you take back control of your health—because no one is coming to do that for you. If you've ever wondered what's actually in your food, how it's affecting your hormones, fertility, or your growing baby, or why the U.S. is behind other countries in banning toxic chemicals… This is your episode. Timestamps: 00:00 Welcome & Why This Matters 01:46 The Hidden Dangers in Our Food 03:18 Meet Kelly Ryerson 03:58 Glyphosate 101 08:20 Why It's So Widely Used (and How It Got That Way) 21:53 The Health Fallout: Gut, Brain, and Beyond 34:27 How to Shop Smarter & Spot Safer Foods 37:58 What Other Countries Are Doing Right 44:37 Why Some Farmers Don't See the Problem 46:07 How Policy, Profit & Pesticides Are All Linked 47:47 Dead Soil = Dead Nutrition 49:28 The Rise of Regenerative Farming 51:06 Safer Options for Home & Garden 55:39 Baby Food Red Flags 58:20 What's Lurking in Juice, Wine & Beer 01:00:50 Nontoxic Yard Care (Your Pets Will Thank You) 01:04:31 Monsanto's Long Game of Deception 01:09:02 Government + Industry: Too Cozy? 01:15:47 Reclaiming Your Family's Health 01:17:59 Final Takeaways + Where to Start Listen now and take the first step toward safer choices, stronger advocacy, and raising a healthier generation. Guest Bio: Kelly Ryerson works at the intersection of agriculture and health. She regularly collaborates with regenerative farmers, scientists, policymakers and media to address agrochemical damage to our soil and bodies. Kelly is the co-Executive Director of American Regeneration and also founded the news site Glyphosate Facts. Kelly has contributed to numerous podcasts, publications, and documentaries including the recent award winning documentary Common Ground. She is an Ambassador for The Rodale Institute. Kelly has a BA from Dartmouth College, an MBA from the Stanford Graduate School of Business, and completed training in integrative health coaching at Duke Integrative Medicine.  INSTAGRAM & SOCIAL MEDIA: Connect with HeHe on IG  Connect with HeHe on YouTube   Connect with Kelly on IG    BIRTH EDUCATION: Join The Birth Lounge here for judgment-free childbirth education that prepares you for an informed birth and how to confidently navigate hospital policy to have a trauma-free labor experience!   Download The Birth Lounge App for birth & postpartum prep delivered straight to your phone!   LINKS MENTIONED: www.americanregeneration.org  www.glyphosatefacts.com  Connect with HRI Labs here Firehawk bio herbicide Pestie  

Rebecca Tickell is an award-winning filmmaker, author, environmental activist, and regenerative farmer. We talked about the journey that led to her films Kiss the Ground and Common Ground, the history of our soil and pesticides, why conventional farming is a cycle of degredation, the corruption of the agrochemical industry, Monsanto whistleblowers, how to feed the world, the global movement of regeneration, how to eat, bees & pollinators, and much more.AirDoctor (Best Rated Air Filters)Get up to $300 off AirDoctorAquaTru (Premium Water Filters)Get $100 off any AquaTru systemSupport the Podcast Directlypatreon.com/somethingdiffpodRebecca's LinksKiss the GroundCommon GroundGroundswellBEE WILDOther References:The Detox ProjectWhitewash by Carey GillamTimestamps:(00:00:00) – Intro(00:03:07) – The road to regeneration(00:11:51) – Storytelling(00:15:02) – Farmers & desertification(00:18:33) – A brief history of our soil(00:27:11) – Connecting to nature(00:28:48) – Two fun facts(00:30:29) – We don't eat our food(00:33:26) – Sacrifice zones & human rights(00:38:21) – Glyphosate, wheat, oats, & chickpeas(00:44:47) – The good news(00:46:09) – Monsanto, Bayer, the EPA, & whistleblowers(00:49:36) – Feeding the world(00:56:04) – Soil regeneration(01:02:41) – A global movement(01:14:49) – How to eat(01:23:10) – USDA Organic(01:29:36) – High stakes(01:30:43) – Bees & insects(01:37:39) – Stories of hope(01:38:59) – Rebecca's dream documentary(01:41:32) – Hopeful

In procurement, tight control over external spend is a golden rule for cost savings. But what would happen if leaders loosened the reins? Malik Akhtar, Chief Procurement Officer at Bayer Consumer Health, tells Zero100 VP, Research Geraint John how the company's "Freedom to Spend Smartly" strategy is putting buying power in the hands of non-procurement users while keeping spend and supplier numbers in check.The why and the how of Freedom to Spend Smartly (00:56) Initial concerns and selling the policy to the CFO (3:20)Managing governance and non-compliance (4:24) How AI is helping procurement leaders and rookie requisitioners (5:22) Decreasing costs, frictionless service, and other early benefits (7:09) Rethinking procurement skills, responsibilities, and incentives (11:28)What's next for Freedom to Spend Smartly (15:18)

Luis Diaz landet heute in München und wird Bayern-Star! Wir haben die Details zum Deal. Außerdem verlässt mit Granit Xhaka der nächste Star Bayer Leverkusen und das wirft die Frage auf, ob die Meisterschaft in diesem Jahr schon vor dem Saisonstart entschieden ist …

Ben Bayer joins Five Minutes with Robert & Amy Nasir LIVE, to discuss his 2025 OCON talk, "America Should Declare Independence from Altruism". We'll ask Dr. Bayer about the State Of The (Moral/Philosophical) Union, how the response to the 2000 pandemic made starkly clear the common moral framework of both America's "left" and "right", why, in Ben's words, "as the right becomes so similar to the left, it is so hostile" to it.  We'll also discuss the decline of "Effective Altruism" and "Longtermism", and why Ayn Rand's morality of self-interest is essential in resolving these failures, injustices, and contradictions. 

Hosts provide updates on MAHA news, including Bayer's ongoing push to shield all pesticide makers from liability, a new controversial aluminum study, and the latest in Guano (Viral Fear-Mongoring) News (hint: Bambi's in trouble).Reference Linkshttps://informedchoicewa.substack.com/https://standforhealthfreedom.com/battles-ahead/food/https://childrenshealthdefense.org/defender/study-claiming-no-link-between-aluminum-vaccines-autism-riddled-flaws/https://globalbiodefense.com/2025/07/20/sars-cov-2-white-tail-deer-viral-reservoir-human-risk/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

So, I'm not sure if this is a slightly “hot take” or not, but regardless…I'm totally fine stating on the record that I believe the Flintstones and Hulk Hogan provided (historically) two of the most impactful positive inflection points involving the children's health supplements market. Initially, children's chewable vitamin tablets were generic in shape…but the game changed forever in 1968 when Miles Laboratories launched Flintstones Chewable Vitamins. By transforming essential nutrients into the beloved characters of the Hanna-Barbera animated sitcom, the product cleverly capitalized on the cartoon's popularity to make vitamin consumption an enjoyable and appealing experience for children. This innovative approach helped demystify vitamins, making them more accessible and less like medicine. And while these revolutionary Flintstones Chewable Vitamins marked the first successful foray into marketing health products to children…Miles Laboratories was hardly an unknown small pharmaceutical company, as it also was responsible for inventing products like Alka-Selzer and One-A-Day vitamins. In fact, Miles Laboratories was generating more than $2 billion in inflation adjusted revenue a half-century ago. And in 1979, when Bayer acquired Miles Laboratories…it became (at the time) the most expensive U.S. acquisition by a foreign pharmaceutical company, ever. Today, while the dominate delivery format of Flintstones Vitamins has evolved with the market preference of gummies…you can still find the standard chewable tablets basically anywhere vitamins are sold in the U.S. market. Also, Flintstones Vitamins are supposedly still the number one pediatrician brand choice for children's chewable vitamins…and reportedly sustains nine-figures of retail sales dollars annually. But then, deploying a vastly different (yet equally) powerful strategy to impact children's dietary habits and perceptions of health and wellness, Hulk Hogan famously said, "say your prayers, eat your vitamins, and be true to yourself." Back in the 1980s and 1990s, Hulk Hogan wasn't just a titan of that specific entertainment genre…he became a cultural icon. Portrayed as a heroic figure who embodied strength, perseverance, a positive attitude…and championed doing the right thing, the larger-than-life persona of Hulk Hogan created a powerful connection with countless "Hulkamaniacs” young (and old). And while not directly associated with a specific vitamin brand at the time when he began incorporating and constantly repeating "eat your vitamins" into his mantra, Hulk Hogan elevated the potentially mundane chore to a vital step in achieving strength and becoming a real-life hero like himself. Though, in the early 1990s…Hulk Hogan finally connected “catchphrase to commerce” by advertising his own line of chewable children's vitamins. And while his chewable vitamins didn't prove successful long-term (especially compared to the Flintstones), the direct endorsement further solidified the link between Hulk Hogan and healthy habits in the minds of children. The exact commercial impact the Flintstones and Hulk Hogan had on the children's health supplements market would be quantifiably impossible for me to obviously figure out. And despite the early childhood and preadolescence stages declining usage rate…multivitamins still account for around 70% of the total children's health supplements market, thus making it the primary underlying driver behind the booming (basically) billion-dollar retail sales category within the U.S. market right now!

In this conversation, Lee and Amy Bayer discuss the complexities of career breaks and re-entering the workforce, particularly focusing on the challenges faced by individuals who take time off for personal reasons such as parenting. Amy shares her personal journey in human resources, her experiences with leadership, and the importance of open communication between employees and employers. They explore the emotional aspects of transitioning back to work, the significance of self-discovery, and the need for patience and persistence in finding fulfilling career opportunities. Additional Resources: 16+ Years in Hospitality Procurement | Supply Chain, Contracting, + Delivering Value to Clients: https://www.linkedin.com/in/amybayer/ Attend Unleashing Leaders University! Learn more about Unleashing Leaders Follow Unleashing Leaders on LinkedIn Connect with Lee on LinkedIn Follow Unleashing Leaders on Facebook Follow Unleashing Leaders on Instagram Key Takeaways: Career breaks can be a source of pride and growth. Open conversations between leaders and employees are crucial. Self-discovery is key to finding fulfillment in work. It's important to recognize and address feelings of depression. The body keeps score of our emotional well-being.